Revenue $7.80B, up 10.2% on a year earlier. Product sales $7.63B, up 8.1%. HIV product sales $5.70B, up 12.0%. Diluted EPS -$8.45 against $1.56.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $7.80B | $6.96B | $7.08B | +10.2% |
| Operating income | -$10.39B | $2.59B | $2.47B | -520.1% |
| Net income | -$10.50B | $2.02B | $1.96B | -635.5% |
| Diluted EPS | -$8.45 | $1.61 | $1.56 | |
| Operating cash flow | $3.57B | $2.54B | $827.00M | +332.0% |
| Capital expenditures | -$140.00M | -$117.00M | -$107.00M | |
| Free cash flow | $3.43B | $2.43B | $720.00M | +376.8% |
| Dividend per share | $0.82 | $0.82 | $0.79 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Product sales | $7.63B | $7.05B | +8.1% |
| HIV product sales | $5.70B | $5.09B | +12.0% |
| Biktarvy sales | $3.77B | $3.53B | +6.9% |
| Descovy sales | $967.00M | $653.00M | +48.1% |
| Yescarta sales | $346.00M | $393.00M | -12.0% |
| Oncology sales | $873.00M | $849.00M | +2.8% |
| Cell Therapy product sales | $417.00M | $485.00M | -14.0% |
| Product sales excluding Veklury | $7.60B | $6.93B | +9.7% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Gilead Sciences (GILD) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/GILD/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
